Explore Abecma Companies for innovative cancer treatment options

Introducing Abecma, the first BCMA-directed CAR T cell therapy approved by the FDA for the treatment of multiple myeloma. Developed by Beijing BIOOCUS Biotech Ltd., Abecma is a groundbreaking treatment that harnesses the power of the patient's own immune system to target and destroy cancer cells, Abecma works by genetically modifying the patient's T cells to express a chimeric antigen receptor (CAR) that recognizes and targets the B-cell maturation antigen (BCMA) found on the surface of myeloma cells. This innovative therapy has shown promising results in clinical trials, providing a new option for patients who have relapsed or refractory multiple myeloma, Beijing BIOOCUS Biotech Ltd. is committed to advancing the field of cellular immunotherapy and bringing innovative treatments to patients in need. With the approval of Abecma, the company continues to demonstrate its dedication to improving the lives of cancer patients worldwide